![David Graham Brooks](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Graham Brooks
Direttore/Membro del Consiglio presso BioCrucible Ltd.
Posizioni attive di David Graham Brooks
Società | Posizione | Inizio | Fine |
---|---|---|---|
BioCrucible Ltd.
![]() BioCrucible Ltd. BiotechnologyHealth Technology Part of Sapphiros, BioCrucible Ltd. is a British company that develops high-performance molecular consumer diagnostics. The company is based in Cambridge, UK. BioCrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation. The company aims to develop proprietary molecular detection technologies deploying ultra-rapid isothermal nucleic acid amplification that enable near-patient and at-home testing for infectious disease or genetic indications. The company was founded in 2018 by Niall Antony Armes. Per Grufman has been the CEO of the company since January 20, 2023. BioCrucible was acquired by Sapphiros on July 21, 2021. | Direttore/Membro del Consiglio | 01/07/2021 | - |
Storia della carriera di David Graham Brooks
Statistiche
Distribuzione geografica
Regno Unito | 2 |
Posizioni
Director/Board Member | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
BioCrucible Ltd.
![]() BioCrucible Ltd. BiotechnologyHealth Technology Part of Sapphiros, BioCrucible Ltd. is a British company that develops high-performance molecular consumer diagnostics. The company is based in Cambridge, UK. BioCrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation. The company aims to develop proprietary molecular detection technologies deploying ultra-rapid isothermal nucleic acid amplification that enable near-patient and at-home testing for infectious disease or genetic indications. The company was founded in 2018 by Niall Antony Armes. Per Grufman has been the CEO of the company since January 20, 2023. BioCrucible was acquired by Sapphiros on July 21, 2021. | Health Technology |
- Borsa valori
- Insiders
- David Graham Brooks
- Esperienza